Abstract 362P
Background
Continuity of care is an important domain of provision of Palliative services. Round the clock Consultation liaison services are provided to all registered Patients (through an on-call number manned by the Resident on call). The Investigator's phone number is bieng provided upon Patient request. Advice regarding symptomatic management (including titration of analgesia), counseling regarding goals of care and opportunity to facilitate a liaison with the Patient's Local physician are bieng provided via telephonic consult. Text messages also form a frequent means of providing important treatment related information.
Methods
29 patients who had contacted this Resident during a period extending from November 2017 to May 2019 were invited to take part in an Investigator initiated Telephonic survey.
Results
11 respondents who were also primary caregivers agreed to participate. The remainder either were unreachable or declined to participate. 5/11 respondents had contacted the on call number while 7/11 had contacted the Investigator's number more than twice. 4/7 were satisfied with the response that they received on the on call number. 2 out of 10 respondents had used the number facilitating a liaison between the Resident and Local Physician. There was unanimous agreement on the feasibility and appropriateness of the on call liaison for provision of Bereavement services. There was consensus that the gender of the Resident did not affect Patient preferences. All respondents agreed that the text message had been an important means of disseminating information. Difficult to control pain was identified as the leading indication for seeking a Telephonic liaison. 3/11 respondents opined that the on-call number should be more accessible. 5/7 respondents agreed that they could have been provided better end of life care. Pain, reduced oral intake and constipation were identified as symptoms that caused the maximum amount of concern during the terminal phase of decline. Two caregivers used the opportunity to air grievances about quality of patient care services that they were provided.
Conclusions
Telephonic liaison services have the potential to act as an effective mode of delivery of palliative (including end of life care) services.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Dr. Rahul D. Arora, Senior Resident, Dept. of Palliative Medicine, All India Institute of Medical Scinces, New Delhi, India.
Funding
Has not received any funding.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
465P - A phase IIIb open-label study of afatinib in EGFR TKI-naïve patients (pts) with EGFR mutation-positive (EGFRm+) NSCLC: Exploratory biomarker analysis
Presenter: Jie Wang
Session: Poster display session
Resources:
Abstract
470P - Prognostic significance of serum biomarkers in small cell lung cancer: A meta-analysis and systematic review
Presenter: Rogelio Velasco
Session: Poster display session
Resources:
Abstract
471P - Chemotherapy in advanced thymic malignancies
Presenter: Ankur Varshney
Session: Poster display session
Resources:
Abstract
466P - Cancer immunotherapy efficacy and patients’ age: A systematic review and meta-analysis
Presenter: Yu Jiang
Session: Poster display session
Resources:
Abstract
506P - Efficacy and safety of pegvorhyaluronidase alfa (PEGPH20; PVHA) and pembrolizumab (pembro) combination therapy in patients (Pts) with stage III/IV non-small cell lung cancer (NSCLC)
Presenter: Jeffrey Ward
Session: Poster display session
Resources:
Abstract
480P - Safety and efficacy of dacomitinib for EGFR+ NSCLC in the subgroup of Asian patients from ARCHER 1050
Presenter: Tony S.K. Mok
Session: Poster display session
Resources:
Abstract
503P - Activity of afatinib in patients (pts) with NSCLC harboring uncommon EGFR mutations: Pooled analysis of three large phase IIIB trials
Presenter: Antonio Passaro
Session: Poster display session
Resources:
Abstract
488P - Randomized trial of prophylactic minocycline for erlotinib-associated skin rash in non-small cell lung cancer (PEARL trial)
Presenter: Kei Kusaka
Session: Poster display session
Resources:
Abstract
495P - Tracking of activating EGFR mutations predicts progression-free survival in advanced EGFR-mutated NSCLC patients treated with osimertinib
Presenter: Anna Buder
Session: Poster display session
Resources:
Abstract
520P - A phase II study to evaluate abscopal effect by palliative radiation therapy in nivolumab treatment for pretreated non-small cell lung cancer (HANSHIN 0116)
Presenter: Akito Hata
Session: Poster display session
Resources:
Abstract